The global market for Novel Drug Delivery Systems (NDDS) is expected to hit USD 320 billion by the year 2021.
Unprecedented developments in genomics and molecular biology today offer a plethora of new drug targets. The method by which a drug is delivered to these targets can have a significant impact on its efficacy. Some drugs have an optimum concentration spectrum within which maximum benefit is derived, and concentrations out of this range can be toxic or produce no therapeutic benefit at all. This, with the very slow progress in the efficacy of the treatment of severe diseases, has suggested a growing need for a multidisciplinary approach to the delivery of therapeutics to targets in tissues. It is estimated that close to 50% of the newly developed drugs cannot be taken orally.
This increase in numbers for the NDDS market is to be driven by the increased requirement for improving the efficacy, safety and bio-recognition of drugs for disease-specific sites within the body, and also the need to improve the comfort levels of patient who are the users of the drugs.
These requirements have led to the need for controlling the pharmacokinetics, pharmacodynamics, non-specific toxicity, immunogenicity, bio-recognition, and efficacy of drugs, in turn leading to the birth of drug delivery systems. The introduction of novel delivery systems to an existing molecule should significantly improve its safety, efficacy, and patient compliance. Most of the innovator companies have a parallel research pipeline for biopharmaceuticals and concentrate also on innovative delivery platforms.
The market has been segmented by route of administration (oral, injectable, pulmonary, transdermal and others) and by geography (North America, Europe, Asia-Pacific and the Rest of the World).
Some of the key players in the market are:
What the Report Offers